STAT3 (signal transducer and activator of transcription 3) is key in regulating the anti-tumor immune response and a therapeutic target of immune therapies in different cancer subtypes such as celecoxib in colorectal cancer and pyrimethamine in chronic lymphocytic leukemia (Zou et al., 2020). This evidence concerns the gene STAT3 and B-cell chronic lymphocytic leukemia.